Prospective Multicentre Validation of a Landmark Machine Learning Model for ICU Mortality in Neurocritical Care (LANDMARK-ICU)
A Prospective Multicentre Observational Study Validating a Landmark-Based Machine Learning Model for Dynamic Prediction of Mortality in Patients Receiving Continuous Intracranial Pressure Monitoring
Mortality prediction in neurocritical care relies on scores computed at admission, which cannot update as the clinical course evolves. We previously developed a landmark-based machine learning model that converts hourly physiological data, including intracranial pressure, into an updating risk of death. The model was developed in a large public database and validated retrospectively in a second, independent one. This prospective multicentre study will test the model in consecutive patients at participating hospitals in Fujian Province, China. Physiological data will be collected as part of routine care. The model will generate risk estimates that are recorded for analysis but not shown to treating clinicians, and no treatment decision will be influenced by the study. The primary analysis will assess discrimination and calibration of the model for death during the intensive care stay. Secondary analyses will compare the model with severity scores in routine use and examine performance by aetiology.
研究概览
地位
详细说明
Model development used the Medical Information Mart for Intensive Care IV database and external validation used the eICU Collaborative Research Database. Both analyses were retrospective and are not part of this registration. This registration covers the prospective multicentre validation only. Inclusion requires age 18 years or older, continuous intracranial pressure monitoring for at least 24 hours, and a diagnosis of traumatic brain injury, aneurysmal subarachnoid haemorrhage or intracerebral haemorrhage. The model uses seven hourly physiological channels with observation masks and elapsed-time features. The primary endpoint is death during the intensive care stay; 28-day mortality, length of stay and Glasgow Outcome Scale at 6 months are secondary. The sample size of 100 patients follows the approved protocol, which assumed area under the curve 0.80 with alpha 0.05 and beta 0.20.
研究类型
注册 (估计的)
联系人和位置
学习地点
-
-
Fujian
-
Fuzhou、Fujian、中国
- Fujian Provincial Hospital
-
Fuzhou、Fujian、中国
- First Affiliated Hospital of Fujian Medical University
-
Quanzhou、Fujian、中国
- Hui'an County Hospital
-
Quanzhou、Fujian、中国
- Second Affiliated Hospital of Fujian Medical University
-
Quanzhou、Fujian、中国
- Shishi City Hospital
-
Zhangzhou、Fujian、中国
- Zhangzhou Municipal Hospital
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
取样方法
研究人群
Adults in intensive care units of participating hospitals who require continuous intracranial pressure monitoring after acute brain injury.
描述
Inclusion Criteria:
- Age 18 years or older
- Continuous intracranial pressure monitoring for at least 24 hours
- Diagnosis of traumatic brain injury, aneurysmal subarachnoid haemorrhage or intracerebral haemorrhage
- Written informed consent from the patient or a legal representative
Exclusion Criteria:
- Incomplete or unusable intracranial pressure recordings
- Loss to follow-up or unavailable outcome information
- Pre-existing severe neurological disease that would confound assessment
学习计划
研究是如何设计的?
设计细节
- 观测模型:COHORT
- 时间观点:PROSPECTIVE
队列和干预
团体/队列 |
干预/治疗 |
|---|---|
|
Neurocritical care cohort
Consecutive patients receiving continuous intracranial pressure monitoring, contributing to the risk set at each landmark. |
Observational application of a fixed prediction model to hourly physiological data; no treatment is assigned or withheld. |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Area under the receiver operating characteristic curve (range 0 to 1) for death during the intensive care stay at the 24-hour landmark
大体时间:24 hours after intensive care admission, with the outcome followed to intensive care unit discharge or day 28
|
Discrimination of the locked landmark model, quantified as the area under the receiver operating characteristic curve, where 0.5 indicates no discrimination and 1.0 perfect discrimination. Death is ascertained from the medical record and the curve is estimated with a 95% confidence interval |
24 hours after intensive care admission, with the outcome followed to intensive care unit discharge or day 28
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Area under the receiver operating characteristic curve (range 0 to 1) for death during the intensive care stay at the 48-hour and 72-hour landmarks
大体时间:48 and 72 hours after intensive care admission, with the outcome followed to intensive care unit discharge or day 28
|
Same measurement as the primary outcome, estimated separately at the 48-hour and 72-hour landmarks with 95% confidence intervals |
48 and 72 hours after intensive care admission, with the outcome followed to intensive care unit discharge or day 28
|
|
Calibration slope (dimensionless) of the landmark model at the 24-, 48- and 72-hour landmarks
大体时间:24, 48 and 72 hours after intensive care admission
|
Slope obtained by logistic regression of the observed outcome on the logit of the predicted risk; a value of 1 indicates perfect calibration, below 1 indicates over-fitting and above 1 under-fitting. |
24, 48 and 72 hours after intensive care admission
|
|
Brier score (range 0 to 1) of the landmark model at the 24-, 48- and 72-hour landmarks
大体时间:24, 48 and 72 hours after intensive care admission
|
Mean squared difference between predicted risk and observed outcome, where lower values indicate better overall performance. |
24, 48 and 72 hours after intensive care admission
|
|
Difference in area under the receiver operating characteristic curve (range -1 to 1) between the landmark model and the centre-recorded APACHE II score
大体时间:24, 48 and 72 hours after intensive care admission
|
Paired difference in discrimination, computed as model area under the curve minus APACHE II area under the curve on the same patients, with 95% confidence interval; negative values indicate the model discriminates worse than APACHE II |
24, 48 and 72 hours after intensive care admission
|
|
Net benefit (dimensionless) of the landmark model from decision-curve analysis at the 24-hour landmark
大体时间:24 hours after intensive care admission
|
Net benefit computed across threshold probabilities from 0.05 to 0.50, compared with the strategies of treating all patients and treating none |
24 hours after intensive care admission
|
|
Area under the receiver operating characteristic curve (range 0 to 1) by primary diagnosis at the 24-, 48- and 72-hour landmarks
大体时间:24, 48 and 72 hours after intensive care admission
|
Discrimination estimated separately for traumatic brain injury, aneurysmal subarachnoid haemorrhage and intracerebral haemorrhage, reported descriptively because stratum sizes are expected to be small |
24, 48 and 72 hours after intensive care admission
|
|
28-day all-cause mortality, as specified in the approved protocol
大体时间:28 days after intensive care admission
|
28 days after intensive care admission
|
|
|
Length of intensive care stay
大体时间:From intensive care admission to intensive care unit discharge, up to 28 days
|
Duration of intensive care stay in days, right-censored at day 28 for patients still in intensive care |
From intensive care admission to intensive care unit discharge, up to 28 days
|
|
Glasgow Outcome Scale score (range 1 to 5, higher is better) at 6 months
大体时间:6 months after intensive care admission
|
Glasgow Outcome Scale, an ordinal scale from 1 (death) to 5 (good recovery), with higher scores indicating better outcome; assessed by telephone or outpatient follow-up |
6 months after intensive care admission
|
合作者和调查者
合作者
调查人员
- 首席研究员:Han Chen, MD、Fujian Provincial Hospital
研究记录日期
研究主要日期
学习开始 (估计的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- FJPH-ICP-01
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
De-identified individual participant data will not be shared publicly because small centre volumes could permit re-identification. The model specification, analysis code and summary results will be published.
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.